NCT06040905 · COMPLETED
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
Sponsor: Chung Shan Medical University
This trial is testing whether a daily coenzyme Q10 supplement (300 mg per day for 12 weeks) improves cognitive function, blood sugar control, and muscle-related markers in people already diagnosed with mild cognitive impairment or Alzheimer's disease who also have elevated blood sugar or early muscle loss. It is a Phase NA randomized placebo-controlled study — meaning it is designed to test cause and effect but is not a standard drug-approval phase trial.
You may qualify if
- Clinical diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD).
- Hyperglycemia, defined as fasting plasma glucose ≥100 mg/dL or current use of glucose-lowering medication.
- Either without sarcopenia risk or with pre-sarcopenia/sarcopenia risk, as determined by calf circumference, handgrip strength, or muscle endurance.
- Ability to swallow tablets.
You're excluded if
- Cancer.
- Severe cardiac, pulmonary, hepatic, or renal disease.
- Severe disability or aphasia.
- Malnutrition (body weight change >5% within one month).
- Current use of coenzyme Q10 supplements.
- Current warfarin therapy.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-21